Matches in SemOpenAlex for { <https://semopenalex.org/work/W2911336504> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2911336504 endingPage "S30" @default.
- W2911336504 startingPage "S30" @default.
- W2911336504 abstract "Background Melphalan (Mel) as a single agent is the most common conditioning regimen prior to autologous stem cell transplantation (ASCT) for multiple myeloma (MM). Incorporation of other drug classes such as proteasome inhibitors (PI) as part of initial therapy or for treatment of relapsed disease has significantly improved outcomes in MM. Based on initial data showing synergy between PI and alkylating agents, we designed this trial to examine if adding carfilzomib (Cfz) to Mel would improve the efficacy of the conditioning therapy. Patients and Methods Patients with MM, undergoing a single, early transplant (≤12 months from diagnosis) were included provided they were eligible for full dose Mel conditioning. Escalating doses of Cfz (27, 36, 45, 56 mg/m2) were administered days -6, -5, -2, -1 with Mel (200 mg/m2) administered in two divided doses on days -4, -3. Stem cells were infused day 0. The phase 1 portion of the trial used a 3+3 dose escalation of Cfz. Responses were assessed using IMWG consensus response criteria. Results 49 patients were enrolled (Table 1). At median follow up of 12.9 months (0.4-48.4), 45 (91.8%) were alive; 41 (83.7%) were without progression. Responses outlined in Table 2. Median PFS from registration was 48.2 mos (95% CI; 21.3-NA). The 1 & 2-year PFS rates were 88.2% (70.5-95.5%) and 71.0% (45.9-86.1%), respectively. Overall, 6 patients had ≥ 1 dose of Cfz omitted (elevated creatinine-3, and 1 patient each with sinus bradycardia, pulmonary edema with atrial fibrillation and rapid ventricular response, and pathologic fracture requiring surgery). A ≥grade 3 hematological or non-hematological toxicity, regardless of attribution, occurred in 94% and 76%, respectively. ≥Grade 3 non-hematological toxicities seen in >1 patient are shown in Figure 1. Conclusion Adding Cfz to Mel as conditioning therapy for ASCT in MM is feasible/safe. Response rates and PFS are comparable to those seen in recent phase 3 trials." @default.
- W2911336504 created "2019-02-21" @default.
- W2911336504 creator A5001453763 @default.
- W2911336504 creator A5012403700 @default.
- W2911336504 creator A5012884078 @default.
- W2911336504 creator A5015118591 @default.
- W2911336504 creator A5026574827 @default.
- W2911336504 creator A5033220547 @default.
- W2911336504 creator A5044733637 @default.
- W2911336504 creator A5045591167 @default.
- W2911336504 creator A5056260546 @default.
- W2911336504 creator A5058688409 @default.
- W2911336504 creator A5068637846 @default.
- W2911336504 creator A5072502164 @default.
- W2911336504 creator A5074505099 @default.
- W2911336504 creator A5076611748 @default.
- W2911336504 creator A5077686486 @default.
- W2911336504 creator A5084606047 @default.
- W2911336504 date "2019-03-01" @default.
- W2911336504 modified "2023-09-27" @default.
- W2911336504 title "Phase 1/2 Trial of Carfilzomib and Melphalan Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma (CARAMEL)" @default.
- W2911336504 doi "https://doi.org/10.1016/j.bbmt.2018.12.102" @default.
- W2911336504 hasPublicationYear "2019" @default.
- W2911336504 type Work @default.
- W2911336504 sameAs 2911336504 @default.
- W2911336504 citedByCount "1" @default.
- W2911336504 countsByYear W29113365042020 @default.
- W2911336504 crossrefType "journal-article" @default.
- W2911336504 hasAuthorship W2911336504A5001453763 @default.
- W2911336504 hasAuthorship W2911336504A5012403700 @default.
- W2911336504 hasAuthorship W2911336504A5012884078 @default.
- W2911336504 hasAuthorship W2911336504A5015118591 @default.
- W2911336504 hasAuthorship W2911336504A5026574827 @default.
- W2911336504 hasAuthorship W2911336504A5033220547 @default.
- W2911336504 hasAuthorship W2911336504A5044733637 @default.
- W2911336504 hasAuthorship W2911336504A5045591167 @default.
- W2911336504 hasAuthorship W2911336504A5056260546 @default.
- W2911336504 hasAuthorship W2911336504A5058688409 @default.
- W2911336504 hasAuthorship W2911336504A5068637846 @default.
- W2911336504 hasAuthorship W2911336504A5072502164 @default.
- W2911336504 hasAuthorship W2911336504A5074505099 @default.
- W2911336504 hasAuthorship W2911336504A5076611748 @default.
- W2911336504 hasAuthorship W2911336504A5077686486 @default.
- W2911336504 hasAuthorship W2911336504A5084606047 @default.
- W2911336504 hasBestOaLocation W29113365041 @default.
- W2911336504 hasConcept C126322002 @default.
- W2911336504 hasConcept C126894567 @default.
- W2911336504 hasConcept C141071460 @default.
- W2911336504 hasConcept C143998085 @default.
- W2911336504 hasConcept C2776063141 @default.
- W2911336504 hasConcept C2776364478 @default.
- W2911336504 hasConcept C2778684742 @default.
- W2911336504 hasConcept C2779050716 @default.
- W2911336504 hasConcept C2780108899 @default.
- W2911336504 hasConcept C2911091166 @default.
- W2911336504 hasConcept C71924100 @default.
- W2911336504 hasConceptScore W2911336504C126322002 @default.
- W2911336504 hasConceptScore W2911336504C126894567 @default.
- W2911336504 hasConceptScore W2911336504C141071460 @default.
- W2911336504 hasConceptScore W2911336504C143998085 @default.
- W2911336504 hasConceptScore W2911336504C2776063141 @default.
- W2911336504 hasConceptScore W2911336504C2776364478 @default.
- W2911336504 hasConceptScore W2911336504C2778684742 @default.
- W2911336504 hasConceptScore W2911336504C2779050716 @default.
- W2911336504 hasConceptScore W2911336504C2780108899 @default.
- W2911336504 hasConceptScore W2911336504C2911091166 @default.
- W2911336504 hasConceptScore W2911336504C71924100 @default.
- W2911336504 hasIssue "3" @default.
- W2911336504 hasLocation W29113365041 @default.
- W2911336504 hasOpenAccess W2911336504 @default.
- W2911336504 hasPrimaryLocation W29113365041 @default.
- W2911336504 hasRelatedWork W1973621728 @default.
- W2911336504 hasRelatedWork W2093665884 @default.
- W2911336504 hasRelatedWork W2144075794 @default.
- W2911336504 hasRelatedWork W2159773146 @default.
- W2911336504 hasRelatedWork W2468113158 @default.
- W2911336504 hasRelatedWork W2549241178 @default.
- W2911336504 hasRelatedWork W2614471822 @default.
- W2911336504 hasRelatedWork W2911336504 @default.
- W2911336504 hasRelatedWork W4206470418 @default.
- W2911336504 hasRelatedWork W2154159148 @default.
- W2911336504 hasVolume "25" @default.
- W2911336504 isParatext "false" @default.
- W2911336504 isRetracted "false" @default.
- W2911336504 magId "2911336504" @default.
- W2911336504 workType "article" @default.